Cargando…

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery

Background: Systemic treatment options for metastatic renal cell carcinoma (RCC) have significantly expanded in recent years. However, patients refractory to tyrosine kinase and immune checkpoint inhibitors still have limited treatment options and patient-individualized approaches are largely missin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jielin, Pohl, Laura, Schüler, Julia, Korzeniewski, Nina, Reimold, Philipp, Kaczorowski, Adam, Hou, Weibin, Zschäbitz, Stefanie, Nientiedt, Cathleen, Jäger, Dirk, Hohenfellner, Markus, Duensing, Anette, Duensing, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227814/
https://www.ncbi.nlm.nih.gov/pubmed/34072926
http://dx.doi.org/10.3390/biomedicines9060627
_version_ 1783712610496020480
author Li, Jielin
Pohl, Laura
Schüler, Julia
Korzeniewski, Nina
Reimold, Philipp
Kaczorowski, Adam
Hou, Weibin
Zschäbitz, Stefanie
Nientiedt, Cathleen
Jäger, Dirk
Hohenfellner, Markus
Duensing, Anette
Duensing, Stefan
author_facet Li, Jielin
Pohl, Laura
Schüler, Julia
Korzeniewski, Nina
Reimold, Philipp
Kaczorowski, Adam
Hou, Weibin
Zschäbitz, Stefanie
Nientiedt, Cathleen
Jäger, Dirk
Hohenfellner, Markus
Duensing, Anette
Duensing, Stefan
author_sort Li, Jielin
collection PubMed
description Background: Systemic treatment options for metastatic renal cell carcinoma (RCC) have significantly expanded in recent years. However, patients refractory to tyrosine kinase and immune checkpoint inhibitors still have limited treatment options and patient-individualized approaches are largely missing. Patients and Methods: In vitro drug screening of tumor-derived short-term cultures obtained from seven patients with clear cell RCC was performed. For one patient, a patient-derived xenograft (PDX) mouse model was established for in vivo validation experiments. Drug effects were further investigated in established RCC cell lines. Results: The proteasome inhibitor carfilzomib was among the top hits identified in three of four patients in which an in vitro drug screening could be performed successfully. Carfilzomib also showed significant acute and long-term cytotoxicity in established RCC cell lines. The in vivo antitumoral activity of carfilzomib was confirmed in a same-patient PDX model. The cytotoxicity of carfilzomib was found to correlate with the level of accumulation of ubiquitinated proteins. Conclusions: In this proof-of-concept study, we show that patient-individualized in vitro drug screening and preclinical validation is feasible. However, the fact that carfilzomib failed to deliver a clinical benefit in RCC patients in a recent phase II trial unrelated to the present study underscores the complexities and limitations of this strategy.
format Online
Article
Text
id pubmed-8227814
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82278142021-06-26 Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery Li, Jielin Pohl, Laura Schüler, Julia Korzeniewski, Nina Reimold, Philipp Kaczorowski, Adam Hou, Weibin Zschäbitz, Stefanie Nientiedt, Cathleen Jäger, Dirk Hohenfellner, Markus Duensing, Anette Duensing, Stefan Biomedicines Article Background: Systemic treatment options for metastatic renal cell carcinoma (RCC) have significantly expanded in recent years. However, patients refractory to tyrosine kinase and immune checkpoint inhibitors still have limited treatment options and patient-individualized approaches are largely missing. Patients and Methods: In vitro drug screening of tumor-derived short-term cultures obtained from seven patients with clear cell RCC was performed. For one patient, a patient-derived xenograft (PDX) mouse model was established for in vivo validation experiments. Drug effects were further investigated in established RCC cell lines. Results: The proteasome inhibitor carfilzomib was among the top hits identified in three of four patients in which an in vitro drug screening could be performed successfully. Carfilzomib also showed significant acute and long-term cytotoxicity in established RCC cell lines. The in vivo antitumoral activity of carfilzomib was confirmed in a same-patient PDX model. The cytotoxicity of carfilzomib was found to correlate with the level of accumulation of ubiquitinated proteins. Conclusions: In this proof-of-concept study, we show that patient-individualized in vitro drug screening and preclinical validation is feasible. However, the fact that carfilzomib failed to deliver a clinical benefit in RCC patients in a recent phase II trial unrelated to the present study underscores the complexities and limitations of this strategy. MDPI 2021-05-31 /pmc/articles/PMC8227814/ /pubmed/34072926 http://dx.doi.org/10.3390/biomedicines9060627 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Jielin
Pohl, Laura
Schüler, Julia
Korzeniewski, Nina
Reimold, Philipp
Kaczorowski, Adam
Hou, Weibin
Zschäbitz, Stefanie
Nientiedt, Cathleen
Jäger, Dirk
Hohenfellner, Markus
Duensing, Anette
Duensing, Stefan
Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
title Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
title_full Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
title_fullStr Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
title_full_unstemmed Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
title_short Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
title_sort targeting the proteasome in advanced renal cell carcinoma: complexity and limitations of patient-individualized preclinical drug discovery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227814/
https://www.ncbi.nlm.nih.gov/pubmed/34072926
http://dx.doi.org/10.3390/biomedicines9060627
work_keys_str_mv AT lijielin targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT pohllaura targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT schulerjulia targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT korzeniewskinina targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT reimoldphilipp targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT kaczorowskiadam targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT houweibin targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT zschabitzstefanie targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT nientiedtcathleen targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT jagerdirk targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT hohenfellnermarkus targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT duensinganette targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery
AT duensingstefan targetingtheproteasomeinadvancedrenalcellcarcinomacomplexityandlimitationsofpatientindividualizedpreclinicaldrugdiscovery